|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Munagala R, Aqil F, Vadhanam MV and Gupta
RC: MicroRNA ‘signature’ during estrogen-mediated mammary
carcinogenesis and its reversal by ellagic acid intervention.
Cancer Lett. 339:175–184. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shin VY, Siu JM, Cheuk I, Ng EK and Kwong
A: Circulating cell-free miRNAs as biomarker for triple-negative
breast cancer. Br J Cancer. 112:1751–1759. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Negrini M and Calin GA: Breast cancer
metastasis: A microRNA story. Breast Cancer Res. 10:2032008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human MicroRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lerebours F, Cizeron-Clairac G, Susini A,
Vacher S, Mouret-Fourme E, Belichard C, Brain E, Alberini JL,
Spyratos F, Lidereau R and Bieche I: miRNA expression profiling of
inflammatory breast cancer identifies a 5-miRNA signature
predictive of breast tumor aggressiveness. Int J Cancer.
133:1614–1623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Long J, Ou C, Xia H, Zhu Y and Liu D:
MiR-503 inhibited cell proliferation of human breast cancer cells
by suppressing CCND1 expression. Tumour Biol. 36:8697–8702. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Polioudakis D, Abell NS and Iyer VR:
miR-503 represses human cell proliferation and directly targets the
oncogene DDHD2 by non-canonical target pairing. BMC Genomics.
16:402015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
King H, Aleksic T, Haluska P and Macaulay
VM: Can we unlock the potential of IGF-1R inhibition in cancer
therapy? Cancer Treat Rev. 40:1096–1105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Crudden C, Girnita A and Girnita L:
Targeting the IGF-1R: The tale of the tortoise and the hare. Front
Endocrinol (Lausanne). 6:642015.PubMed/NCBI
|
|
14
|
Singh P, Alex JM and Bast F: Insulin
receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R)
signaling systems: Novel treatment strategies for cancer. Med
Oncol. 31:8052014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dricu A, Kanter L, Wang M, Nilsson G,
Hjertman M, Wejde J and Larsson O: Expression of the insulin-like
growth factor 1 receptor (IGF-1R) in breast cancer cells: Evidence
for a regulatory role of dolichyl phosphate in the transition from
an intracellular to an extracellular IGF-1 pathway. Glycobiology.
9:571–579. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Al Sarakbi W, Chong YM, Williams SL,
Sharma AK and Mokbel K: The mRNA expression of IGF-1 and IGF-1R in
human breast cancer: Association with clinico-pathological
parameters. J Carcinog. 5:162006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kucab JE and Dunn SE: Role of IGF-1R in
mediating breast cancer invasion and metastasis. Breast Dis.
17:41–47. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hou X, Huang F, Macedo LF, Harrington SC,
Reeves KA, Greer A, Finckenstein FG, Brodie A, Gottardis MM,
Carboni JM and Haluska P: Dual IGF-1R/InsR inhibitor BMS-754807
synergizes with hormonal agents in treatment of estrogen-dependent
breast cancer. Cancer Res. 71:7597–7607. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen Y, Zhu C, Peng Z, Dai Y and Gu Y:
Lentivirus-mediated short-hairpin RNA targeting IGF-1R inhibits
growth and lymphangiogenesis in breast cancer. Oncol Rep.
28:1778–1784. 2012.PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang K, Jia Z, Zou J, Zhang A, Wang G, Hao
J, Wang Y, Yang S and Pu P: Analysis of hsa-miR-30a-5p expression
in human gliomas. Pathol Oncol Res. 19:405–411. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kimura S, Naganuma S, Susuki D, Hirono Y,
Yamaguchi A, Fujieda S, Sano K and Itoh H: Expression of microRNAs
in squamous cell carcinoma of human head and neck and the
esophagus: miR-205 and miR-21 are specific markers for HNSCC and
ESCC. Oncol Rep. 23:1625–1633. 2010.PubMed/NCBI
|
|
23
|
Visone R, Pallante P, Vecchione A,
Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V,
Borbone E, et al: Specific microRNAs are downregulated in human
thyroid anaplastic carcinomas. Oncogene. 26:7590–7595. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu J, Zeng Y, Xu C, Qin H, Lei Z, Shen D,
Liu Z and Huang JA: Expression profile analysis of microRNAs and
downregulated miR-486-5p and miR-30a-5p in non-small cell lung
cancer. Oncol Rep. 34:1779–1786. 2015.PubMed/NCBI
|
|
25
|
Jia Z, Wang K, Wang G, Zhang A and Pu P:
MiR-30a-5p antisense oligonucleotide suppresses glioma cell growth
by targeting SEPT7. PLoS One. 8:e550082013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang X, Wang K, Han L, Zhang A, Shi Z,
Zhang K, Zhang H, Yang S, Pu P, Shen C, et al: PRDM1 is directly
targeted by miR-30a-5p and modulates the Wnt/β-catenin pathway in a
Dkk1-dependent manner during glioma growth. Cancer Lett.
331:211–219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dai H, Kang B, Zuo D and Zuo G: Effect of
miR-30a-5p on the proliferation, apoptosis, invasion and migration
of SMCC-7721 human hepatocellular carcinoma cells. Zhonghua Gan
Zang Bing Za Zhi. 22:915–920. 2014.(In Chinese). PubMed/NCBI
|
|
28
|
Baraniskin A, Birkenkamp-Demtroder K,
Maghnouj A, Zöllner H, Munding J, Klein-Scory S, Reinacher-Schick
A, Schwarte-Waldhoff I, Schmiegel W and Hahn SA: MiR-30a-5p
suppresses tumor growth in colon carcinoma by targeting DTL.
Carcinogenesis. 33:732–739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ruiz-Llorente L, Ardila-González S, Fanjul
LF, Martinez-Iglesias O and Aranda A: microRNAs 424 and 503 are
mediators of the anti-proliferative and anti-invasive action of the
thyroid hormone receptor beta. Oncotarget. 5:2918–2933. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen J, Duan Y, Zhang X, Ye Y, Ge B and
Chen J: Genistein induces apoptosis by the inactivation of the
IGF-1R/p-Akt signaling pathway in MCF-7 human breast cancer cells.
Food Funct. 6:995–1000. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Heskamp S, Boerman OC, Molkenboer-Kuenen
JD, Wauters CA, Strobbe LJ, Mandigers CM, Bult P, Oyen WJ, van der
Graaf WT and van Laarhoven HW: Upregulation of IGF-1R expression
during neoadjuvant therapy predicts poor outcome in breast cancer
patients. PLoS One. 10:e01177452015. View Article : Google Scholar : PubMed/NCBI
|
